公开(公告)号：EP3340803B1

公开(公告)日：2024-06-26

申请号：EP16760436.2

申请日：2016-08-26

IPC分类号： A61K31/37 ,  A23L2/00 ,  A61K38/01 ,  C07D311/80 ,  A61P21/00 ,  A23L2/52 ,  A23L2/66 ,  A23L33/19 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/14 ,  A61K38/17 ,  A61K47/42 ,  A61P25/00

CPC分类号： A61K38/01 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/08 ,  A61K47/42 ,  A61K9/146 ,  A61K31/37 ,  A23L2/66 ,  A23V2002/0020130101 ,  A23L33/40 ,  A23L33/105 ,  A23L33/19 ,  A23L2/52 ,  C07D311/80 ,  A61P21/00 ,  A61P25/00 ,  A61K38/018 ,  A61K38/1709

公开(公告)号：EP3592425A1

公开(公告)日：2020-01-15

申请号：EP18712107.4

申请日：2018-03-08

申请人： Amazentis SA

发明人： RINSCH, Christopher ,  ANDREUX, Penelope ,  SINGH, Anurag

IPC分类号： A61P3/00 ,  C07D311/80 ,  A61K31/366

公开(公告)号：EP4395771A1

公开(公告)日：2024-07-10

申请号：EP22823616.2

申请日：2022-08-30

申请人： Amazentis SA

发明人： RINSCH, Christopher, L. ,  SINGH, Anurag ,  D'AMICO, Davide

IPC分类号： A61K31/37 ,  A61P31/14 ,  A61P31/12 ,  A61P31/22 ,  A61P21/00 ,  A61K31/122 ,  A61K31/375 ,  A61K31/7084 ,  A61K31/706 ,  A61K33/30

CPC分类号： A61K31/37 ,  A61P31/14 ,  A61P31/12 ,  A61P31/22 ,  A61P21/00 ,  A61K31/375 ,  A61K31/122 ,  A61K31/7084 ,  A61K31/706 ,  A61K33/30

公开(公告)号：EP3592424A1

公开(公告)日：2020-01-15

申请号：EP18712106.6

申请日：2018-03-08

申请人： Amazentis SA

发明人： RINSCH, Christopher ,  ANDREUX, Penelope ,  SINGH, Anurag

IPC分类号： A61P3/00 ,  A61K31/366 ,  C07D311/80

公开(公告)号：EP3369420A1

公开(公告)日：2018-09-05

申请号：EP18166897.1

申请日：2011-12-23

申请人： Amazentis SA

发明人： RINSCH, Christopher ,  ANDREUX, Penelope ,  SCHNEIDER, Bernard ,  SANDI, Carmen ,  AUWERX, Johan ,  PIRINEN, Eija ,  THOMAS, Charles ,  HOUTKOOPER, Richardus ,  BLANCO-BOSE, William ,  MOUCHIROUD, Laurent ,  GENOUX, David

IPC分类号： A61K31/352 ,  A61K36/00 ,  A61K36/185 ,  A23L33/105

CPC分类号： A61K31/366 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0056 ,  A61K31/352 ,  A61K31/7048 ,  A61K36/185 ,  Y02A50/401

摘要： Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

公开(公告)号：EP2654461B1

公开(公告)日：2018-04-11

申请号：EP11808119.9

申请日：2011-12-23

申请人： Amazentis SA

发明人： ANDREUX, Penelope ,  SCHNEIDER, Bernard ,  RINSCH, Christopher, L. ,  SANDI, Carmen ,  AUWERX, Johan ,  PIRINEN, Eija ,  THOMAS, Charles ,  HOUTKOOPER, Richardus ,  BLANCO-BOSE, William ,  MOUCHIROUD, Laurent ,  GENOUX, David

IPC分类号： A23L33/105

CPC分类号： A61K31/366 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0056 ,  A61K31/352 ,  A61K31/7048 ,  A61K36/185 ,  Y02A50/401

摘要： Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

公开(公告)号：EP3087065A2

公开(公告)日：2016-11-02

申请号：EP14828105.8

申请日：2014-12-22

申请人： Amazentis SA

发明人： RINSCH, Christopher, L. ,  MÜLLER, Roland ,  SKRANC, Wolfgang

IPC分类号： C07D311/80

CPC分类号： C07D311/80 ,  A61K31/366 ,  A61K33/34

摘要： Disclosed is a method of preparing a urolithin, or an intermediate or analog thereof, having a dibenzo[b,d]pyran-6-one core. The method is especially advantageous for the large-scale preparation of urolithins or intermediates or analogs thereof. The method may optionally include the preparation of a urolithin, or an intermediate or analog thereof, as a pharmaceutically acceptable salt.

摘要翻译： 公开了制备具有二苯并[b，d]吡喃-6-酮核心的尿石素或其中间体或类似物的方法。 该方法对于大规模制备尿石素或其中间体或类似物是特别有利的。 该方法可以任选地包括制备尿石素或其中间体或类似物作为药学上可接受的盐。

公开(公告)号：EP3087064B1

公开(公告)日：2021-09-15

申请号：EP14824845.3

申请日：2014-12-23

发明人： RINSCH, Christopher Lawrence ,  RINGOM, Rune Andreas

IPC分类号： C07D311/80 ,  A61K31/366 ,  A61P3/00

公开(公告)号：EP3278800B1

公开(公告)日：2019-04-10

申请号：EP17186188.3

申请日：2011-12-23

申请人： Amazentis SA

发明人： RINSCH, Christopher ,  SCHNEIDER, Bernard ,  ANDREUX, Pénélope ,  SANDI, Carmen ,  AUWERX, Johan ,  PIRINEN, Eija ,  THOMAS, Charles ,  HOUTKOOPER, Richardus ,  BLANCO-BOSE, William ,  MOUCHIROUD, Laurent ,  GENOUX, David

IPC分类号： A61K31/352 ,  A61K36/00 ,  A61K36/185

公开(公告)号：EP3372228A1

公开(公告)日：2018-09-12

申请号：EP18166896.3

申请日：2011-12-23

申请人： Amazentis SA

发明人： RINSCH, Christopher ,  ANDREUX, Penelope ,  SCHNEIDER, Bernard ,  SANDI, Carmen ,  AUWERX, Johan ,  PIRINEN, Eija ,  THOMAS, Charles ,  HOUTKOOPER, Richardus ,  BLANCO-BOSE, William ,  MOUCHIROUD, Laurent ,  GENOUX, David

IPC分类号： A61K31/352 ,  A61K36/00 ,  A61K36/185 ,  A23L33/105

CPC分类号： A61K31/366 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0056 ,  A61K31/352 ,  A61K31/7048 ,  A61K36/185 ,  Y02A50/401

摘要： Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.